Antiproliferative Effects of Sclerotial Polysaccharides from Polyporus rhinocerus Cooke (Aphyllophoromycetideae) on Different Kinds of Leukemic Cells

2008 ◽  
Vol 10 (3) ◽  
pp. 255-264 ◽  
Author(s):  
Connie K. M. Lai ◽  
Ka-Hing Wong ◽  
Peter Chi Keung Cheung
PLoS ONE ◽  
2011 ◽  
Vol 6 (10) ◽  
pp. e25651 ◽  
Author(s):  
Aurore Beaulieu ◽  
Géraldine Poncin ◽  
Zakia Belaid-Choucair ◽  
Chantal Humblet ◽  
Gordana Bogdanovic ◽  
...  

2009 ◽  
Vol 2 (1) ◽  
pp. 46-IN3 ◽  
Author(s):  
Victoria Cavaliere ◽  
Daniela L. Papademetrio ◽  
Mario Lorenzetti ◽  
Pamela Valva ◽  
María Victoria Preciado ◽  
...  

2009 ◽  
Vol 76 (6) ◽  
pp. 1314-1322 ◽  
Author(s):  
Shary N. Shelton ◽  
Mary E. Shawgo ◽  
Shawna B. Matthews ◽  
Yuanming Lu ◽  
Alison C. Donnelly ◽  
...  

2005 ◽  
Vol 29 (4) ◽  
pp. 415-421 ◽  
Author(s):  
M. Pilátová ◽  
M. Šarišský ◽  
P. Kutschy ◽  
A. Miroššay ◽  
R. Mezencev ◽  
...  

Author(s):  
A.J. Mia ◽  
L.X. Oakford ◽  
T. Yorio

Protein kinase C (PKC) isozymes, when activated, are translocated to particulate membrane fractions for transport to the apical membrane surface in a variety of cell types. Evidence of PKC translocation was demonstrated in human megakaryoblastic leukemic cells, and in cardiac myocytes and fibroblasts, using FTTC immunofluorescent antibody labeling techniques. Recently, we reported immunogold localizations of PKC subtypes I and II in toad urinary bladder epithelia, following 60 min stimulation with Mezerein (MZ), a PKC activator, or antidiuretic hormone (ADH). Localization of isozyme subtypes I and n was carried out in separate grids using specific monoclonal antibodies with subsequent labeling with 20nm protein A-gold probes. Each PKC subtype was found to be distributed singularly and in discrete isolated patches in the cytosol as well as in the apical membrane domains. To determine if the PKC isozymes co-localized within the cell, a double immunogold labeling technique using single grids was utilized.


Planta Medica ◽  
2009 ◽  
Vol 75 (09) ◽  
Author(s):  
AD Weber ◽  
CZ Stüker ◽  
G Zannon ◽  
V Ilha ◽  
II Dalcol ◽  
...  

Planta Medica ◽  
2016 ◽  
Vol 81 (S 01) ◽  
pp. S1-S381 ◽  
Author(s):  
H Niksic ◽  
E Kovac-Besovic ◽  
M Sober ◽  
N Mulabegovic ◽  
M Kralj ◽  
...  

1995 ◽  
Vol 73 (03) ◽  
pp. 535-542 ◽  
Author(s):  
N Crawford ◽  
A Chajara ◽  
G Pfliegler ◽  
B EI Gamal ◽  
L Brewer ◽  
...  

SummaryDrugs can be electro-encapsulated within platelets and targeted to damaged blood vessels by exploiting the platelet’s natural haemostatic properties to adhere to collagen and other vessel wall constituents revealed by injury. A rat aorta balloon angioplasty model has been used to study the effect on platelet deposition of giving iloprost loaded platelets i.v. during the balloon injury. After labelling the circulating platelets with 111-Indium before balloon injury, time course studies showed maximum platelet deposition on the injured aorta occurred at about 1 h post-injury and the deposition remained stable over the next 2-3 h. When iloprost-loaded platelets were given i.v. during injury and the circulating platelet pool labelled with 111-Indium 30 min later, platelet deposition, measured at 2 h postinjury, was substantially and significantly reduced compared with control platelet treatment. Some antiproliferative effects of iloprost-loaded platelets given i.v. during injury have also been observed. Whereas the incorporation of [3H]-thymidine into aorta intima-media DNA at 3 days post injury was 62-fold higher in balloon injured rats than in control sham operated rats, thymidine incorporation into intima/media of rats which had received iloprost loaded platelets during injury was reduced as compared with rats subjected only to the injury procedure. The reduction was only of near significance, however, but at 14 days after injury the total DNA content of the aorta intima/media of rats given iloprost loaded platelets during injury was significantly reduced. Although iloprost loaded platelets can clearly inhibit excessive platelet deposition, other encapsulated agents may have greater anti-proliferative effects. These studies have shown that drug loaded platelets can be targeted to injured arteries, where they may be retained as depots for local release. We believe this novel drug delivery protocol may have therapeutic potential in reducing the incidence of occlusion and restenosis after angioplasty and thrombolysis treatment. Electro-encapsulation of drugs into platelets is a simple procedure and, using autologous and fully biocompatible and biodegradable platelets as delivery vehicles, might overcome some of the immunological and toxicological problems which have been encountered with other delivery vectors such as liposomes, microbeads, synthetic microcapsules and antibodies.


Sign in / Sign up

Export Citation Format

Share Document